APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

a study on Kidney Disease End Stage Renal Disease Chronic Kidney Disease Kidney Transplant

Summary

Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Chi-yuan Hsu, MDMeyeon Park, MD
Headshot of Chi-yuan Hsu
Chi-yuan Hsu
Headshot of Meyeon Park
Meyeon Park

Description

Summary

The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

Details

The National Institutes of Health (NIH)-sponsored collaborative APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) is charged with prospectively assessing the effects of renal-risk variants (RRVs) in the apolipoprotein L1 gene (APOL1) on outcomes for kidneys from donors with recent African ancestry and the recipients of their kidneys, after deceased- and living-donor renal transplantation. For the purposes of APOLLO, recent African ancestry is defined as individuals with similar genetic make-up to those currently residing in Africa. APOLLO will also study the impact of APOL1 RRVs on the health of living kidney donors with recent African ancestry.

Keywords

Kidney Diseases, Kidney Failure, Kidney Disease, Chronic, Apolopoprotein L1 gene (APOL1), Kidney Transplantation, Kidney Donor, United Network for Organ Sharing (UNOS), Association of Organ Procurement Organizations (AOPO), Kidney Transplantation Outcomes Network, Renal Insufficiency, Chronic Renal Insufficiency, Recipients of a Kidney Transplant, Living Kidney Donors

Eligibility

You can join if…

for Living Donors:

  • Living kidney donors with self-reported recent African ancestry (defined as African American, Afro-Caribbean, Hispanic black or African) will be eligible for inclusion.

You CAN'T join if...

for Living Donors:

  • Participants who are unable or unwilling to provide informed consent.

Enrollment and bio sample collection from deceased donors at OPOs ended on May 31, 2023 and recruiting kidney transplant recipients ended on June 15, 2023.

Phase II started on 9/1/2023 and only Living Donors will be recruited for an additional 2 years.

Locations

  • UCSF accepting new patients
    San Francisco California 94143 United States
  • Saint Louis University Center for Transplantation accepting new patients
    Saint Louis Missouri 63104 United States

Lead Scientists at UCSF

  • Chi-yuan Hsu, MD
    Dr. Hsu has been Chief of the Division of Nephrology at UCSF Health since 2007. He currently holds the Robert W. Schrier Distinguished Professorship in Nephrology. His research spans acute, chronic and end-stage kidney disease and includes both observational studies and clinical trials.
  • Meyeon Park, MD
    My research focuses on patient outcomes in genetic kidney diseases including polycystic kidney disease and APOL1-mediated kidney disease. I am the medical director of the UCSF PKD Center of Excellence and principal investigator of the UCSF Cardiovascular Risk After Kidney Transplantation (CARAKTER) study.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Wake Forest University Health Sciences
ID
NCT03615235
Study Type
Observational
Participants
Expecting 5000 study participants
Last Updated
Contact us about this trial